[Treatment of myelodysplastic syndrome using SM-108 in relation to stem cell kinetics].
Eighteen patients in a high-blast group of myelodysplastic syndrome were treated with low-dose SM-108 (4-carbamoylimidazolium 5-olate). Seven of the 18 patients (38.9%) achieved a partial response, and 4 (22.2%) achieved complete response. Treatment was associated with significant, but transient myelotoxicity. Changes in CFU-GEMM clonal growth were examined in bone marrow from patients during the treatment.
Uzuka
Y
Y
3rd Dept. of Internal Medicine, Tohoku University, School of Medicine.
Saito
Y
Y
D000328:Adult; D000368:Aged; D002453:Cell Cycle / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis
D007093:Imidazoles; C033758:4-carbamoylimidazolium 5-olate